What this study is
Eosinophilic fasciitis is a connective tissue disorder characterized by inflammation of the muscle fasciae, which is very rare in children. In juvenile-onset eosinophilic fasciitis (JEF), there may be severe joint involvement and skin manifestations may be less prevalent than in adults. It represents an important differential diagnosis of both juvenile-onset systemic sclerosis and localized scleroderma, and the correct classification of these patients is necessary to define a targeted diagnostic-therapeutic pathway. The diagnostic criteria proposed for eosinophilic fasciitis in the adult population do not necessarily require confirmation by skin biopsy, currently the "gold standard," which is an invasive procedure for pediatric patients; however, these criteria have never been directly applied to the pediatric population. From a therapeutic point of view, the combination of glucocorticoids and methotrexate is recommended for both adults and pediatric patients, but the data supporting this treatment in children are very limited, and there are no studies comparing the therapeutic approaches currently in use in pediatrics. Finally, there are no studies in the literature documenting the long-term prognosis of these patients in terms of functional limitations, quality of life, or complications related to the disease or treatments.
Study details
- Official title
- International Multicentre Cohort Study on Clinical Manifestations and Response to Therapy in Juvenile Onset Eosinophilic Fasciitis
- Sponsor
- Meyer Children's Hospital IRCCS
- Conditions
- Eosinophilic Fasciitis
- Enrolling
- 20 people
- Starts
- 2025-05-15
- Est. completion
- 2027-05-15
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age Up to 18 YearsSex ALLHealthy volunteers Not acceptedYou may qualify if
- All patients diagnosed from 2000 to 31/12/2026
- Minimum follow-up 6 months
- Age <18 years at diagnosis;
- All patients whose informed consent is collected in accordance with current local legislation will also be considered enrollable.
You can't join if
- Age ≥18 years at diagnosis;
- Unwilling to participate into the study;
- A follow-up period < 6 months.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (15)
15 openUniversity of Alabama at Birmingham
Birmingham, Alabama, United States
RecruitingSUNY Upstate Pediatric Rheumatology
Syracuse, New York, United States
Recruiting
13 sites outside the US
Children's Hospital Zagreb
Zagreb, Croatia
RecruitingHamburger Zentrum für Kinder- und Jugendrheumatologie -
Hamburg, Germany
- Ivan Foldvari · Contactfoeldvari@t-online.de
Not yet recruitingRuth Rappaport Children's Hospital of Haifa
Haifa, Israel
Not yet recruitingMeyer Children's Hospital IRCCS
Florence, FI, Italy
- Edoardo Marrani · Contact+390555662913edoardo.marrani@meyer.it
Recruiting- Recruiting
- Not yet recruiting
Iuliu Hatieganu University of Medicine and Pharmacy
Cluj-Napoca, Romania
Recruiting- Not yet recruiting
- Not yet recruiting
Astrid Lindgren Children's Hospital
Solna, Stockholm County, Sweden
RecruitingCerrahpasa Medical School, Istanbul University
Istanbul, Turkey (Türkiye)
Not yet recruitingAlder Hey Children's Hospital
Liverpool, United Kingdom
- Clare Pain · ContactClare.Pain@alderhey.nhs.ukClare.Pain@alderhey.nhs.uk
RecruitingGreat North Children's Hospital, Newcastle Upon Tyne
Newcastle upon Tyne, United Kingdom
- Miguel Bernardo · Contactmiguelbernardo.mb92@gmail.com
Not yet recruiting
Study team
Sponsor
Meyer Children's Hospital IRCCS
Study ID EFESO
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.